Table 3. Prevalence of LMP-1 3′... | American Society of Hematology

Table 3.

Prevalence of LMP-1 3′ Deletions in EBV⁺ Lymphoproliferative Disorders From HIV-Seronegative and HIV-Infected Patients

	Hodgkin's Disease		Non-Hodgkin's Lymphomas
	HIV-Seronegative (%)	HIV-Seropositive (%)	HIV-Seronegative (%)	HIV-Seropositive (%)
Full-length LMP-1	18/30 (60)	2/12 (16.7)	3/5 (60)	3/7 (42.9)
LMP-1 3′ deletion	12/30^3-150 (40)	10/12 (83.3)^3-151	2/5 (40)	4/7 (57.1)

	Hodgkin's Disease		Non-Hodgkin's Lymphomas
	HIV-Seronegative (%)	HIV-Seropositive (%)	HIV-Seronegative (%)	HIV-Seropositive (%)
Full-length LMP-1	18/30 (60)	2/12 (16.7)	3/5 (60)	3/7 (42.9)
LMP-1 3′ deletion	12/30^3-150 (40)	10/12 (83.3)^3-151	2/5 (40)	4/7 (57.1)

Two of these cases carried a deletion larger than 30 bp.

The prevalence of LMP-1 deletions in HIV-related HD is significantly higher (P = .01) than that detected in HD from HIV-seropositive patients.